A new study by Leila Setayesh and team showed that adults benefit from amla supplementation in terms of metabolic markers. The findings of this study were published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
Emblica Officinalis (Amla) is a plant that has been used in traditional medicine for its antioxidant, anti-inflammatory, hypoglycemic, and hypolipidemic characteristics. Unfortunately, there is currently little evidence that it can prevent or cure metabolic disorders linked with chronic illnesses. As a result, this study was carried out to evaluate the effects of Amla on the lipid profile, glucose, and C-reactive protein, consequently treating chronic illnesses.
The purpose of this systematic review and meta-analysis was to look at the effects of Amla supplementation on lipid profile, glucose, and C-reactive protein (CRP) levels in adults. A comprehensive search was conducted of all accessible randomized controlled trials (RCTs) in databases such as ISI Web of Science, Scopus, PubMed, and Embase (as of December 2022). A random-effects model was used to compute the mean difference (MD) of each effect. A random-effects model was also used to generate the weighted mean difference (WMD) and 95% confidence intervals (CIs).
The key findings of this study were:
The meta-analysis comprised five RTCs.
A significant decrease in CRP (p = 0.002), fasting blood glucose (p = 0.001), low-density lipoprotein cholesterol (LDL-c) (p = 0.001), total cholesterol (p = 0.001), and serum triglyceride (TG) (p = 0.001) were observed after Amla supplementation, while an increase in high-density lipoprotein cholesterol (p = 0.001) was observed.
For subgroup analysis, the biochemical indicator baseline concentration was employed.
In conclusion, the people included in the investigation usually ranged in age from 40 to 58, had an average BMI of 25.5 and received interventions lasting between 3 and 12 weeks. Hence, more research is necessary to support and broaden the conclusions made in this article.
Reference:
Setayesh, L., Haghighat, N., Rasaei, N., Rezaei, M., Casazza, K., Nadery, M., yamrali, I., Zamani, M., & Asbaghi, O. (2023). The impact of Emblica Officinalis (Amla) on lipid profile, glucose, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. In Diabetes & Metabolic Syndrome: Clinical Research & Reviews (Vol. 17, Issue 3, p. 102729). Elsevier BV. https://doi.org/10.1016/j.dsx.2023.102729
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.